GMP-in-a-box com­pa­ny with Bob Nelsen back­ing lands $167M to de­vel­op its own can­cer drugs

For the fourth time in as many weeks, a com­pa­ny fo­cused on portable drug man­u­fac­tur­ing is mak­ing noise.

This time, Nut­crack­er Ther­a­peu­tics has brought in $167 mil­lion in a Se­ries C round led by ARCH Ven­ture Part­ners. The com­pa­ny will use the fi­nanc­ing to help ad­vance its pipelines of mR­NA med­i­cines for on­col­o­gy, in ad­di­tion to re­fin­ing the man­u­fac­tur­ing tech­nol­o­gy that spurred the biotech’s launch. Nut­crack­er will al­so grow its team, par­tic­u­lar­ly on the med­ical side of things, as it has re­cent­ly round­ed out its ex­ec­u­tive team.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER